共 50 条
Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states
被引:6
|作者:
Bruzelius, Emilie
[1
]
Cerda, Magdalena
[2
]
Davis, Corey S.
[2
,3
]
Jent, Victoria
[2
]
Wheeler-Martin, Katherine
[2
]
Mauro, Christine M.
[4
]
Crystal, Stephen
[5
]
Keyes, Katherine M.
[1
]
Samples, Hillary
[5
]
Hasin, Deborah S.
[6
]
Martins, Silvia S.
[1
]
机构:
[1] Columbia Univ, Dept Epidemiol, 722 W 168th St, New York, NY 10032 USA
[2] NYU Grossman Sch Med, Dept Populat Hlth, 180 Madison Ave 4th Floor, New York, NY 10016 USA
[3] Network Publ Hlth Law, 7101 York Ave South, Edina, MN 55435 USA
[4] Columbia Univ, Dept Biostat, 722 W 168th St, New York, NY 10032 USA
[5] Rutgers State Univ, 112 Paterson St, New Brunswick, NJ 08901 USA
[6] Columbia Univ, Dept Psychiat, 722 W 168th St,Room 228F, New York, NY 10032 USA
关键词:
Naloxone;
Adolescent;
Harm reduction;
Injection drug use;
Heroin;
Policy analysis;
UNITED-STATES;
RISK BEHAVIOR;
PRESCRIPTION;
STUDENTS;
ACCESS;
LAWS;
D O I:
10.1016/j.drugpo.2023.103980
中图分类号:
R194 [卫生标准、卫生检查、医药管理];
学科分类号:
摘要:
Background: Naloxone distribution is central to ongoing efforts to address the opioid overdose crisis. Some critics contend that naloxone expansion may inadvertently promote high-risk substance use behaviors among adoles-cents, but this question has not been directly investigated. Methods: We examined relationships between naloxone access laws and pharmacy naloxone distribution with lifetime heroin and injection drug use (IDU), 2007-2019. Models generating adjusted odds ratios (aOR) and 95% confidence intervals (CI) included year and state fixed effects, controlled for demographics and sources of variation in opioid environments (e.g., fentanyl penetration), as well as additional policies expected to impact substance use (e.g., prescription drug monitoring). Exploratory and sensitivity analyses further examined nalox-one law provisions (e.g., third-party prescribing) and applied e-value testing to assess vulnerability to unmeasured confounding. Results: Adoption of any naloxone law was not associated with changes in adolescent lifetime heroin or IDU. For pharmacy dispensing, we observed a small decrease in heroin use (aOR: 0.95 [CI: 0.92, 0.99]) and a small increase in IDU (aOR: 1.07 [CI: 1.02, 1.11]). Exploratory analyses of law provisions suggested that third-party prescribing (aOR: 0.80, [CI: 0.66, 0.96]) and non-patient-specific dispensing models (aOR: 0.78, [CI: 0.61, 0.99]) were associated with decreased heroin use but not decreased IDU. Small e-values associated with the pharmacy dispensing and provision estimates indicate that unmeasured confounding may explain observed findings. Conclusion: Naloxone access laws and pharmacy naloxone distribution were more consistently associated with decreases rather than increases in lifetime heroin and IDU among adolescents. Our findings therefore do not support concerns that naloxone access promotes high-risk adolescent substance use behaviors. As of 2019, all US states have adopted legislation to improve naloxone access and facilitate use. However, further removal of adolescent naloxone access barriers is an important priority given that the opioid epidemic continues to affect people of all ages
引用
收藏
页数:8
相关论文